Description
Hemlibra 150mg Injection is a groundbreaking medication used for the treatment of Hemophilia A, a genetic bleeding disorder. Its active ingredient, emicizumab, is a bispecific monoclonal antibody that mimics the function of a missing clotting factor (Factor VIII) in the blood. By bridging activated Factor IX and Factor X, emicizumab facilitates the conversion of prothrombin to thrombin, thereby promoting effective blood clot formation and reducing the frequency of bleeding episodes. Hemlibra is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding in patients with Hemophilia A with or without factor VIII inhibitors. The dosage and administration should be determined by a healthcare professional based on the patient’s weight and clinical response. Common side effects may include injection site reactions, headache, and joint pain. It is crucial to store Hemlibra 150mg Injection as per the manufacturer’s instructions, typically refrigerated and protected from light. Always consult your doctor for personalized medical advice and before making any changes to your treatment regimen.
